Evidence map›Paper›PMID 28225996›Full record

Trial reportArchives of endocrinology and metabolism

Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control.

Miriam Méndez-Del Villar, Esperanza Martínez-Abundis, Rafael O Preciado-Márquez, Manuel González-Ortiz

Registry-linked trialOpen access · diamondFull text readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Archives of endocrinology and metabolism. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06912035 (EFFICACY OF DIACEREIN ADDITION ON INTERLEUKIN-1Β, HS-CRP, TNF-Α LEVELS AND GLYCEMIC CONTROL IN UNCONTROLLED TYPE 2 DIABETES MELLITUS PATIENTS AT DR. MOHAMMAD HOESIN GENERAL HOSPITAL PALEMBANG), which is not on this map. Cited by 11 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 3 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06912035 phase2 / phase3completednot on this map

Efficacy of diacerein addition on interleukin-1β, hs-crp, tnf-α levels and glycemic control in uncontrolled type 2 diabetes mellitus patients at dr. mohammad hoesin general hospital palembang

TypeinterventionalSponsorUniversitas SriwijayaRan2024 to 2024Enrolled34ConditionsUncontrolled Diabetes, Diabetes Mellitus Type 2ArmsDiacerein 50 mg Capsule, Placebo
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 3 syntheses or guidelines pooled it, 27 citations in OpenAlex.

  1. Association of type 2 diabetes and osteoarthritis: an umbrella review of systematic reviews and meta-analyses.European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Efficacy and safety ofTherapeutics and clinical risk management · 2018
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Miriam Méndez-Del VillarInstitute of Experimental and Clinical Therapeutics, Physiology Department, Health Science University Center, University of Guadalajara, Guadalajara, Mexico.
Esperanza Martínez-AbundisInstitute of Experimental and Clinical Therapeutics, Physiology Department, Health Science University Center, University of Guadalajara, Guadalajara, Mexico.
Rafael O Preciado-MárquezInstitute of Experimental and Clinical Therapeutics, Physiology Department, Health Science University Center, University of Guadalajara, Guadalajara, Mexico.
Manuel González-OrtizInstitute of Experimental and Clinical Therapeutics, Physiology Department, Health Science University Center, University of Guadalajara, Guadalajara, Mexico.
Universidad de Guadalajara · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus (T2DM) and inadequate glycemic control. MATERIALS AND

methodsA randomized, double-blind, placebo-controlled clinical trial was carried out on 12 patients with T2DM and inadequate glycemic control [glycated hemoglobin A1c (A1C) ≥ 7%] with metformin as monotherapy (≥ 1500 mg per day) for at least the previous 90 days. Fasting and postprandial glucose were measured before and after the pharmacological intervention. A1C, lipid profile, creatinine and uric acid were also evaluated. After randomization, all patients continued with their dose of metformin. Six subjects received placebo and the other six volunteers took diacerein. Data were tested using the Wilcoxon signed-rank, Mann-Whitney U and chi-square tests. The Institutional Ethics Committee approved the study protocol.

resultsAfter 90 days of diacerein as an add-on to metformin, there was a significant decrease in fasting glucose (196 ± 79 vs. 149 ± 70 mg/dL, p < 0.05), postprandial glucose (262 ± 99 vs. 187 ± 70 mg/dlL, p < 0.05) and A1C (8.4 ± 2.0 vs. 6.7 ± 1.7 %, p < 0.05).

conclusionsDiacerein as an add-on to metformin in patients with T2DM improved their glycemic control.

Indexed as

AdultAnthraquinonesAnti-Inflammatory AgentsBlood GlucoseDiabetes Mellitus, Type 2Dose-Response Relationship, DrugDouble-Blind MethodDrug Therapy, CombinationFemaleGlycated HemoglobinHumansHypoglycemic AgentsMaleMetforminMiddle AgedOverweightAnthraquinonesAnti-Inflammatory AgentsBlood GlucosediacereinGlycated HemoglobinHypoglycemic AgentsMetforminPlacebos

Identifiers

PMID28225996
PMCPMC10118867
OpenAlexW2588157280

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.